How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?

Yonsei Med J. 2009 Feb 28;50(1):83-8. doi: 10.3349/ymj.2009.50.1.83. Epub 2009 Feb 24.

Abstract

Purpose: Although warfarin is an effective oral anticoagulation (OAC) drug to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation (NVAF), long term follow-up data are scarce to be certain whether the target INR level is maintained in warfarin-treated patients in Korea. The aim of this study was to evaluate how well INRs are maintained within the target range using a new index, INR stability (= 100 x number of INRs within target range/total number of INR measurements) which we made, and to find out any correlation between thromboembolic events and INR stability.

Materials and methods: This study was an observational analysis of retrospectively collected data of 129 patients with NVAF from April 2000 to December 2005 at a single tertiary hospital. All patients were registered at the anticoagulation service.

Results: The median duration of follow up was 2.03 years (interquartile range 1.35 - 2.96). During the follow-up period, 60.9 +/- 14.9% of the INR were within the target INR range. INR stability was not significantly different between patients without and with stroke (61.2 +/- 15.0% vs 53.3 +/- 4.9%). Among the known factors affecting fluctuations of the INR value, the most frequent factor was noncompliance (41.8%).

Conclusion: The present study showed that it was not enough to maintain INR values within the target range in warfarin-treated patients with NVAF even at a tertiary hospital. Noncompliance is an important problem which interferes with maintaining target INR range.

Keywords: Anticoagulation; atrial fibrillation.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / etiology
  • Drug Monitoring / methods
  • Female
  • Follow-Up Studies
  • Heart Valves
  • Humans
  • International Normalized Ratio*
  • Male
  • Middle Aged
  • Patient Compliance
  • Retrospective Studies
  • Risk Factors
  • Thrombosis / blood*
  • Thrombosis / epidemiology
  • Thrombosis / prevention & control*
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin